Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients.
Several population-wide HIV-1 subtype distribution studies in Uganda have evaluated relatively healthy clinic patients. Given the differences in HIV-1 disease progression based on subtype, we examined HIV-1 subtype distribution and disease outcomes among hospitalized patients with severe sepsis.Pati...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3483180?pdf=render |
| _version_ | 1828425055152898048 |
|---|---|
| author | Najah I Doka Shevin T Jacob Patrick Banura Christopher C Moore David Meya Harriet Mayanja-Kizza Steven J Reynolds W Michael Scheld Wen Yuan |
| author_facet | Najah I Doka Shevin T Jacob Patrick Banura Christopher C Moore David Meya Harriet Mayanja-Kizza Steven J Reynolds W Michael Scheld Wen Yuan |
| author_sort | Najah I Doka |
| collection | DOAJ |
| description | Several population-wide HIV-1 subtype distribution studies in Uganda have evaluated relatively healthy clinic patients. Given the differences in HIV-1 disease progression based on subtype, we examined HIV-1 subtype distribution and disease outcomes among hospitalized patients with severe sepsis.Patients with severe sepsis were enrolled at two hospitals in Uganda. Data collected included demographics, Karnofsky scores, highly active antiretroviral therapy (HAART) use, HIV-1 serostatus, CD4+ T cell concentration, whole blood lactate concentration, and blood cultures. HIV-1 subtypes were determined by sequencing parts of the gag and env genes, followed by phylogenetic analysis.Of the 267 patients evaluated, 228 (85.4%) were HIV infected. The predominant HIV-1 subtypes were A (46%), D (17%), and AD recombinants (30%). HIV-1 subtypes B, C, and other recombinants were uncommon. Patients infected with HIV-1 subtypes A, D and AD viruses were similar in demographics, CD4(+) T cell concentration, HAART use, Karnofsky scores, whole blood lactate concentration, and positive blood cultures. There was no difference in 30-day mortality from severe sepsis between the 3 groups (p = 0.99).A high proportion of HIV-1 subtypes A and AD recombinants was observed in this cohort of severely septic patients. The proportion of AD recombinants was higher in this cohort than in previous cohorts of Ugandan HIV-1 patients. No difference in baseline demographics, clinical factors or 30-day mortality was seen across HIV-subtypes. |
| first_indexed | 2024-12-10T16:25:49Z |
| format | Article |
| id | doaj.art-69422494cff14ae98b11ecdfe9e91d15 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T16:25:49Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-69422494cff14ae98b11ecdfe9e91d152022-12-22T01:41:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01710e4835610.1371/journal.pone.0048356Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients.Najah I DokaShevin T JacobPatrick BanuraChristopher C MooreDavid MeyaHarriet Mayanja-KizzaSteven J ReynoldsW Michael ScheldWen YuanSeveral population-wide HIV-1 subtype distribution studies in Uganda have evaluated relatively healthy clinic patients. Given the differences in HIV-1 disease progression based on subtype, we examined HIV-1 subtype distribution and disease outcomes among hospitalized patients with severe sepsis.Patients with severe sepsis were enrolled at two hospitals in Uganda. Data collected included demographics, Karnofsky scores, highly active antiretroviral therapy (HAART) use, HIV-1 serostatus, CD4+ T cell concentration, whole blood lactate concentration, and blood cultures. HIV-1 subtypes were determined by sequencing parts of the gag and env genes, followed by phylogenetic analysis.Of the 267 patients evaluated, 228 (85.4%) were HIV infected. The predominant HIV-1 subtypes were A (46%), D (17%), and AD recombinants (30%). HIV-1 subtypes B, C, and other recombinants were uncommon. Patients infected with HIV-1 subtypes A, D and AD viruses were similar in demographics, CD4(+) T cell concentration, HAART use, Karnofsky scores, whole blood lactate concentration, and positive blood cultures. There was no difference in 30-day mortality from severe sepsis between the 3 groups (p = 0.99).A high proportion of HIV-1 subtypes A and AD recombinants was observed in this cohort of severely septic patients. The proportion of AD recombinants was higher in this cohort than in previous cohorts of Ugandan HIV-1 patients. No difference in baseline demographics, clinical factors or 30-day mortality was seen across HIV-subtypes.http://europepmc.org/articles/PMC3483180?pdf=render |
| spellingShingle | Najah I Doka Shevin T Jacob Patrick Banura Christopher C Moore David Meya Harriet Mayanja-Kizza Steven J Reynolds W Michael Scheld Wen Yuan Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. PLoS ONE |
| title | Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. |
| title_full | Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. |
| title_fullStr | Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. |
| title_full_unstemmed | Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. |
| title_short | Enrichment of HIV-1 subtype AD recombinants in a Ugandan cohort of severely septic patients. |
| title_sort | enrichment of hiv 1 subtype ad recombinants in a ugandan cohort of severely septic patients |
| url | http://europepmc.org/articles/PMC3483180?pdf=render |
| work_keys_str_mv | AT najahidoka enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT shevintjacob enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT patrickbanura enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT christophercmoore enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT davidmeya enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT harrietmayanjakizza enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT stevenjreynolds enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT wmichaelscheld enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients AT wenyuan enrichmentofhiv1subtypeadrecombinantsinaugandancohortofseverelysepticpatients |